Back to resultsA Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
Primary Purpose
Mesothelioma
Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin
Sponsored by
About this trial
This is an interventional treatment trial for Mesothelioma
Eligibility Criteria
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed malignant pleural mesothelioma, epithelial, sarcomatoid, or mixed subtype
- Patients must have measurable disease,using RECIST criteria.Pleural effusions and ascites are not considered measurable lesions.
- Patients with pleural mesothelioma must be IMIG stage ≥II
- Age greater than or equal to 18 years.
- ECOG performance status less than or equal to 2 and an estimated survival of at least 3 months
- Patients must have adequate organ and marrow function as defined below:
Absolute neutrophil count greater than or equal to1,500 Platelets greater than or equal to 100,000 Total bilirubin less than or equal to2.0x the upper limits of institutional normal AST/ALT less than or equal to 2.0x the upper limits of institutional normal Creatinine Clearance greater than 50ml/min
- The effects of VEGF-AS on the developing human fetus are unknown.
- Pemetrexed may cause fetal harm when administered to a pregnant woman and is classified pregnancy category D. There are no studies of pemetrexed in pregnant women. Cisplatin is also categorized as FDA Pregnancy Category D. There is positive evidence of human fetal risk. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent.
- Patients with history of prior cured malignancy > 5 years since the completion of treatment may be accrued provided that other eligibility criteria are met.
Exclusion Criteria:
- Patients who have had chemotherapy for Mesothelioma prior to study entry
- Patients who have had radiation therapy within 3 weeks prior to entering the study. All patients should have recovered from all toxicities of prior therapy.
- Patients receiving therapy with other investigational agents at the time of study enrollment.
- Patients with uncontrolled brain metastases
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant and nursing women are excluded from this study
- Patients who had any major surgery within 4 weeks
Sites / Locations
- USC/Norris Comprehensive Cancer Center
Outcomes
Primary Outcome Measures
The primary endpoint of the phase II trial will be time to progression
Secondary Outcome Measures
Secondary endpoints are objective response rate and overall survival
Full Information
NCT ID
NCT00668499
First Posted
April 25, 2008
Last Updated
May 19, 2014
Sponsor
University of Southern California
Collaborators
Sponsor Name Pending
1. Study Identification
Unique Protocol Identification Number
NCT00668499
Brief Title
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
Official Title
A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor withdrew support
Study Start Date
April 2008 (undefined)
Primary Completion Date
April 2011 (Anticipated)
Study Completion Date
April 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University of Southern California
Collaborators
Sponsor Name Pending
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This will be a single institution non-randomized phase I/II trial for patients with malignant mesothelioma stage II and above, who have not received prior chemotherapy for their disease.
The purpose of this phase is to select a dose of VEGF-AS (antiangiogenesis drug)to be given with standard doses of pemetrexed followed by cisplatin on day 1 of a 21-day cycle.
Detailed Description
The Study Objectives in Phase I are:
To determine the safety of the combination of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin™) plus Pemetrexed and Cisplatin in subjects with advanced Malignant Mesothelioma,.via a dose escalation protocol. To determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of VEGF-AS plus Premetrexed and Cisplatin. To determine the time to disease progression To determine the objective response rate of the combination of VEGF-AS plus Pemetrexed and Cisplatin for the treatment of advanced malignant mesothelioma
The study Objectives in Phase II are:
To further characterize the toxicity experienced by patients with malignant mesothelioma treated with VEGF-AS plus Cisplatin and Pemetrexed.
To determine median and overall survival.
The Laboratory objectives are:
To measure plasma VEGF levels before, during, and after therapy as a correlate of outcome. To determine the pharmacokinetic profile of VEGF-AS plus Pemetrexed and Cisplatin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mesothelioma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin
Intervention Description
VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
Primary Outcome Measure Information:
Title
The primary endpoint of the phase II trial will be time to progression
Time Frame
Tumor measurements every 6 weeks
Secondary Outcome Measure Information:
Title
Secondary endpoints are objective response rate and overall survival
Time Frame
Every 6 weeks evaluations
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must have histologically or cytologically confirmed malignant pleural mesothelioma, epithelial, sarcomatoid, or mixed subtype
Patients must have measurable disease,using RECIST criteria.Pleural effusions and ascites are not considered measurable lesions.
Patients with pleural mesothelioma must be IMIG stage ≥II
Age greater than or equal to 18 years.
ECOG performance status less than or equal to 2 and an estimated survival of at least 3 months
Patients must have adequate organ and marrow function as defined below:
Absolute neutrophil count greater than or equal to1,500 Platelets greater than or equal to 100,000 Total bilirubin less than or equal to2.0x the upper limits of institutional normal AST/ALT less than or equal to 2.0x the upper limits of institutional normal Creatinine Clearance greater than 50ml/min
The effects of VEGF-AS on the developing human fetus are unknown.
Pemetrexed may cause fetal harm when administered to a pregnant woman and is classified pregnancy category D. There are no studies of pemetrexed in pregnant women. Cisplatin is also categorized as FDA Pregnancy Category D. There is positive evidence of human fetal risk. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Ability to understand and the willingness to sign a written informed consent.
Patients with history of prior cured malignancy > 5 years since the completion of treatment may be accrued provided that other eligibility criteria are met.
Exclusion Criteria:
Patients who have had chemotherapy for Mesothelioma prior to study entry
Patients who have had radiation therapy within 3 weeks prior to entering the study. All patients should have recovered from all toxicities of prior therapy.
Patients receiving therapy with other investigational agents at the time of study enrollment.
Patients with uncontrolled brain metastases
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant and nursing women are excluded from this study
Patients who had any major surgery within 4 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barbara Gitlitz, MD
Organizational Affiliation
University of Southern California
Official's Role
Principal Investigator
Facility Information:
Facility Name
USC/Norris Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
We'll reach out to this number within 24 hrs